Last updated: 02/18/2024 17:40:28
Efficacy/effectiveness of pazopanib and trabectedin treatment for metastatic synovial sarcoma
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Efficacy/effectiveness of pazopanib and trabectedin treatment for metastatic synovial sarcoma: systematic review and meta-analysis
Trial description: The objective of the study is to evaluate the efficacy/effectiveness of pazopanib and trabectedin for >=2nd line metastatic synovial sarcoma using data from regulatory documents, clinical trials, and observational studies with regards to overall response rate and other listed outcomes.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Overall response rate (ORR)
Timeframe: Up to 17 years
Secondary outcomes:
Overall Survival (OS)
Timeframe: Up to 17 years
Progression free survival (PFS)
Timeframe: Up to 17 years
Number of participants with partial response (PR)
Timeframe: Up to 17 years
Number of participants with stable disease (SD)
Timeframe: Up to 17 years
Interventions:
Not applicable
Enrollment:
0
Primary completion date:
2020-06-04
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Sarcoma, Synovial
Product
GSK3377794
Collaborators
NA
Study date(s)
November 2019 to April 2020
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Adults with metastatic SS.
- Studies among participants with STS, but reporting results for the SS subgroup, are in scope.
- Studies among STS participants will be excluded if they do not report results for the SS subgroup separately.
- Cross-sectional studies, and case reports will be excluded.
Inclusion and exclusion criteria
Inclusion criteria:
- Adults with metastatic SS.
- Studies among participants with STS, but reporting results for the SS subgroup, are in scope.
- Studies where results for adolescents or children are aggregated with adults are also in scope.
- Pazopanib or trabectedin treatment administered in >=2nd line of therapy.
- Studies with the following outcomes of interest: overall response rate; overall survival; progression free survival; partial response and stable disease.
- All study designs are in scope including clinical trials (controlled, single arm, open label), prospective or retrospective cohort studies, and registry studies.
- Clinical studies from 2002 onwards will be included.
Exclusion criteria:
- Studies among STS participants will be excluded if they do not report results for the SS subgroup separately. Cross-sectional studies, and case reports will be excluded.
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2020-06-04
Actual study completion date
2020-06-04
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website